Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Relapsing or Naïve Dermatomyositis
NCT04972760Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2022
- Primary completion
- Feb 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing baricitinib arm with placebo arm (2 arms). Primary endpoint: Moderate improvement without prednisone at 24 weeks. Started Aug 2022; status: recruiting.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04972760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972760.